An observational study in Thyroid Gland Carcinoma, sponsored by Mayo Clinic. Recruiting at 3 sites in United States. Open to participants aged 8 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Thyroid Neoplasms with a site in United States — 53 open to participants now, 88 under way, 3 of them phase 3. Thyroid Neoplasms · United States.
Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 14th largest by planned enrollment of the 47 observational ones that give a count, is one of 9 that started in 2009, is one of 47 observational ones, reaches primary completion later than 24 of the 82 other live ones, and was the 257th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →53 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States, Mexico
Ages 18+
Kaiser Permanente · Sites in United States
Ages 21–45
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Thomas Hope · Sites in United States
Ages 12+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: 8 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 120 · Phase 3 10 · Phase 4 5
First in 1977; this study’s year is marked. 9 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 178 across 241 observational studies indexed under Thyroid Neoplasms.
Median enrollment 35 across the 231 interventional studies, 200 across the 47 observational. Of the 182 that completed or were terminated, 93 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 283 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 7 studies filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
26 of the studies in Thyroid Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03099356University of Michigan Rogel Cancer CenterCyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer | 2026-12 |
| NCT06220656Dartmouth-Hitchcock Medical CenterTRAIL Study: Feasibility and Pilot | 2026-12 |
| NCT05366881Adela, InccfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | 2026-12-31 |
| NCT06207188Mayo ClinicIdentification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters | 2026-12-31 |
| NCT04916990University of Colorado, DenverImproving Care for Rural Patients With Solid Tumors | 2027-01-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 283 studies in Thyroid Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to identify and differentiate thyroid nodules by acoustic imaging and viscoelastic parameters.
PRIMARY OBJECTIVES:
I. Identification of thyroid nodules by vibro-acoustography - Determine detection rate.
II. Evaluate the specificity of VA in differentiating malignant and benign of thyroid nodules - Compare the result to that of ultrasound (US).
III. Assess diagnostic value of Shear Wave Ultrasound Vibrometry (SDUV) and Comb Push shear elastography (CUSE) in differentiation of thyroid nodules - correlate SDUV and CUSE results to pathology.
IV. Test and compare the results shear wave imaging with new FDA approved ultrasound device called SuperSonic Imagine Aixplorer.
V. Assess diagnostic value of Shear Wave Ultrasound Vibrometry (SDUV) and Comb Push shear elastography (CUSE) in differentiation of palpable and sonographically detectable cervical lymph nodes or non-thyroidal neck masses.
VI. Assess the diagnostic values of ultrasound quantitative microvessel imaging for differentiation of thyroid nodules and cervical lymph nodes.
VII. Assess the response to alcohol ablation on patients with recurrent thyroid cancer on thyroid bed or new lymph nodes on neck.
OUTLINE: This is an observational study.
Patients undergo ultrasound imaging on study.
Patient volunteers ages 8 and up who are suspicious for thyroid cancer or a group of patients who have palpable and sonographically detectable lymph nodes or nonthyroidal neck masses or who were previously diagnosed with thyroid cancer and treated with thyroidectomy and recently diagnosed as having recurrence nodes on thyroid bed or on their neck.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* Male and female patient volunteers ages 8 and up who are suspicious for thyroid cancer
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo ultrasound imaging on study.
Other: Non-Interventional Study
Non-interventional study
Incidence of nodules successfully sited by vibro-acoustography (VA)
Successful nodule localization will be assessed by the review of the VA image relative to the nodule location information from the reference ultrasound (US) image (agree/disagree on location will be determined for each nodule).
Time frame: Baseline, 3 months post ablation, 6 months post ablation, 12 months post ablation
Specificity of VA in differentiating malignant and benign of thyroid nodules
Specificity of VA in differentiating malignant and benign of thyroid nodules will be determined by comparing the VA image to the US image.
Time frame: Baseline, 3 months post ablation, 6 months post ablation, 12 months post ablation
Started May 2009 (actual). Primary completion is estimated for Dec 2026, 211 months after the start.
Of 103 non-industry observational studies under Thyroid Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 311. This study's planned 211 months is above that.
Counting every sponsor, half of 112 studies reached it within 63 months; a quarter within 26 and three quarters within 311.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.